Top

Pediatric Surgery International

Published in:

01-10-2008 | Original Article

The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma

Authors: Toshiya Morimura, Keiko Fujita, Masumi Akita, Masabumi Nagashima, Akira Satomi

Published in: Pediatric Surgery International | Issue 10/2008

Abstract

Purpose

In normal physiology, a vacuolar-type proton pump (V-ATPase) maintains an intracellular acid microenvironment in lysosome, endosome, and other endomembrane systems. Cancer cells overexpress V-ATPase compared with normal cells, and disturbances of the acid environment are thought to significantly impact the cancer cell infiltration and growth. Bafilomycin A1 (Baf-A1) is a specific inhibitor of the proton-pump inhibitor (PPI) V-ATPase. Neoplastic cells are reportedly more sensitive to Baf-A1 than normal cells, and the difference between the susceptibility to Baf-A1 in normal cells and that in cancer cells may become a target in the cancer therapy. With this in mind, we used cells of hepatoblastoma, the cancer type accounting for 80% of all childhood liver cancers, to investigate the effects of Baf-A1 as an inducer of cancer cell apoptosis and inhibitor of cancer cell reproduction

Methods and results

Electron microscopy showed significant morphological change of the hepatoblastoma cells of the Baf-A1-treated group compared with hepatoblastoma cells of the Baf-A1-free group. The rate of the apoptotic cell increased, and cell reproduction was inhibited. Moreover, the analysis of hepatoblastoma cells using the gene Chip gene expression analysis arrays showed that three of the 27 V-ATPase-related transcripts (ATP6V0D2, ATP6V1B1, and ATP6V0A1) were more weakly expressed in the Baf-A1-treated cells than in the Baf-A1-free cells. In normal human hepatic cells, on the other hand, the inhibition of cell growth of the Baf-A1-treated cells was negligible compared to that of the cells without Baf-A1 treatment. The result of apoptotic cell detection by morphological observations and flow cytometry revealed that Baf-A1 inhibits hepatoblastoma cellular reproduction by inducing apoptosis. On the other hand, the Baf-A1-conferred inhibition of cell growth was negligible in normal human hepatocytes

Conclusion

The V-ATPase inhibitor Baf-A1 has been proven to selectively inhibit the reproduction and induce the apoptosis of hepatoblastoma cells without adversely influencing normal hepatic cells. With these effects, V-ATPase inhibitors may hold promise as therapeutic agents for hepatoblastoma. Given that three V-ATPase-related genes (ATP6V0D2, ATP6V1B1, and ATP6V0A1) were more weakly expressed in the hepatoblastoma cells of the Baf-A1-treated group than in the Baf-A1-free cells, drug development targeting V-ATPase gene of hepatoblastomas is expected.

Nelson N et al (1989) Structure, molecular genetics, and evolution of vacuolar H⁺-ATPases. J Bioenerg Biomembr 21:553–571PubMedCrossRef

Ohta T, Numata M, Yagishita H et al (1996) Expression of 16 kDa proteolipid of vacuolar-type H⁺-ATPase in human pancreatic cancer. Br J Cancer 73:1511–1517PubMed

Ohkuma S, Shimizu S, Noto M et al (1993) Inhibition of cell growth by bafilomycin A1, a selective inhibitor of vacuolar H⁺-ATPase. In vitro Cell Dev Biol Anim 29A:862–866PubMedCrossRef

Manabe T, Yoshimori T, Henomatsu N et al (1993) Inhibitors of vacuolar-type H⁺-ATPase suppresses proliferation of cultured cells. J Cell Physiol 157:445–452PubMedCrossRef

Ohkuma S, Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and perturbation of pH by various agents. Proc Natl Acad Sci USA 75:3327–3331PubMedCrossRef

Nishihara T, Akifusa S, Koseki T et al (1995) Specific inhibitors of vacuolar type H⁺-ATPase induce apoptotic cell death. Biochem Biophys Res Commun 212:255–262PubMedCrossRef

Bunge RP, Wood P (1973) Studies on the transplantation of spinal cord tissue in the rat. I. The development of a culture system for hemisections of embryonic spinal cord. Brain Res 57:261–276PubMedCrossRef

Perilongo G, Shafford E, Plaschkes J (2000) SIOPEL trials using preoperative chemotherapy in hepatoblastoma. Lancet Oncol 1:94–100PubMedCrossRef

Hurtado-Lorenzo A, Skinner M, Annan JEI et al (2006) V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nat Cell Biol 8:124–136PubMedCrossRef

10.

Martinez-Zaguilan R, Lynch RM, Martinez GM et al (1993) Vacuolar-type H⁺-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 265:1015–1029

11.

Finbow ME, Harrison MA (1997) The vacuolar H⁺-ATPase: a universal proton pump of eukaryotes. Biochem J 324:697–712PubMed

12.

Shrode LD, Tapper H, Gristein S (1997) Role of intracellular pH in proliferation, transformation, and apoptosis. Bioenerg Biomembr 29:393–399CrossRef

13.

Hinton A, Bond S, Forgac M (2007) V-ATPase functions in normal and disease processes. Pflugers Arch. doi: 10.1007/s00424-007-0382-4

14.

Nelson N, Harvey WR et al (1999) Vacuolar and plasma membrane proton adenosinetriphoshatases. Physiol Rev 79:361–385PubMed

15.

Yoshimoto Y, Imoto M (2002) Induction of EGF-dependent apoptosis by vacuolar type H⁺-ATPase inhibitors in A431 cells overexpressing the EGF receptor. Exp Cell Res 279:118–127PubMedCrossRef

16.

Hamada H, Moriyama Y, Maeda N et al (1990) Kinetic studies of chromaffin granule H⁺-ATPase and effects of bafilomycin A1. Biochem Biophys Res Commun 170:873–878CrossRef

17.

Huss M, Sasse F, Kunze B, Kunze B et al (2005) Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem 6:13PubMedCrossRef

18.

Niikura K, Takeshita M, Takano M et al (2005) A vacuolar ATPase inhibitor, FR 167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application. J Bone Miner Res 20:1579–1588PubMedCrossRef

19.

Ohta T, Arakawa H, Futagami F et al (1996) A new strategy for the therapy of pancreatic cancer by proton pump inhibitor. Jpn J Cancer Chemother 23:1660–1664

20.

Nakashima S, Hiraku Y, Oikawa ST (2003) Vacuolar H⁺-ATPase inhibitor induces apoptosis via lysosomal dysfunction in the human gastric cancer cell line MKN-1. J Biochem 134:359–364PubMedCrossRef

21.

Sennoune SR, Bakunts K, Martinez GM et al (2004) Vacuolar H⁺-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:1443–1452CrossRef

22.

Nishi T, Forgac M (2002) The vacuolar H⁺-ATPases—nature’s most versatile proton pumps. Nat Rev Mol Cell Biol 3:94–103PubMedCrossRef

23.

Stevens TH, Forgac M (1997) Structure, function and regulation of the vacuolar H⁺-ATPase. Annu Rev Cell Dev Biol 13:779–808PubMedCrossRef

24.

Pali T, Whyteside G, Dixon N et al (2004) Interaction of inhibitors of the vacuolar H⁺-ATPase with the transmembrane Vo-sector. Biochemistry 43:12297–12305PubMedCrossRef

25.

Bowman EJ, Bowman BJ (2005) V-ATPases as drug targets. J Bioenerg Biomembr 37:431–435PubMedCrossRef

26.

Whyteside G, Meek PJ, Ball SK et al (2005) Concanamycin and indolyl pentadieneamide inhibitors of the vacuolar H⁺-ATPase bind with high affinity to the purified proteolipid subunit of the membrane domain. Biochemistry 44:15024–15031PubMedCrossRef

27.

Otero-Rey EM, Somoza-Martin M, Barros-Angueira F et al (2008) Intercellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over expression of the ATP6V1C1 gene. Oral Oncol 44:193–199PubMedCrossRef

28.

Lu X, Qin W, Li J et al (2005) The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65:6843–6849PubMedCrossRef

29.

Hinoki A, Yoshimura K, Fujita K et al (2006) Suppression of proinflammatory cytokine production in macrophages by lansoprazol. Pediatr Surg Int 22:915–923PubMedCrossRef

Title: The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma
Authors: Toshiya Morimura
Keiko Fujita
Masumi Akita
Masabumi Nagashima
Akira Satomi
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Pediatric Surgery International / Issue 10/2008
Print ISSN: 0179-0358
Electronic ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-008-2229-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The proton pump inhibitor inhibits cell growth and induces apoptosis in human hepatoblastoma

Abstract

Purpose

Methods and results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods and results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2008

An association of gastroschisis and fatal respiratory distress: does prenatal bile aspiration cause early-onset respiratory failure in neonates?

Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone

Difficulties in the management of mesenchymal hamartomas

Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR

Gender assignment and hormonal treatment for disorders of sexual differentiation

Efficacy and safety of balloon-occluded retrograde transvenous obliteration for gastric fundal varices in children